Abstract: Compounds of the Formula I ##STR1## are inhibitors of the 5.alpha.-reductase 1 isozyme, and are useful alone, or in combination with a 5.alpha.-reductase 2 inhibitor, for the treatment of androgenic sensitive disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness, and benign prostatic hyperplasia.

Abstract: Described are new 16-substituted and 7,16-disubstituted 4-aza-5.alpha.-androstan-3-ones and related compounds as 5.alpha.-reductase inhibitors.

Abstract: Novel phosphinic acid-containing peptidyl compounds of formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. These inhibitors may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.

Abstract: Compounds of formula (I), wherein: R.sup.1 is selected from the group consisting of hydrogen and methyl; R.sup.2 is selected from the group consisting of methyl and ethyl; R.sup.3 is selected from the group consisting of hydrogen and methyl; and the C1-C2 carbon-carbon bond may be a single or double bond. Such compounds are useful in the treatment of pathologic conditions that benefit from blockade of isozymes of 5.alpha.-reductase.

Abstract: Disclosed herein are compounds of Formula I ##STR1## and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis.

Abstract: New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. ##STR1## wherein R.sub.4 is (a) ##STR2## or (b) ##STR3## where R.sub.x is carboxy C.sub.1-6 alkyl, benzyloxycarbonylC.sub.1-3 alkyl, or t-butoxycarbonylC.sub.1-3 alkyl,whereinQ is a covalent bond or ##STR4## wherein R.sub.5 and R.sub.6 are each individually C.sub.1-3 alkyl or hydrogen,Y is ##STR5## or a covalent bond.

Abstract: A cooking apparatus including an open housing (1) closed by a lid (8), a cooking vat (4) provided inside the housing, and a cooking vapor condenser device (13) provided outside the housing. At least one vapor outlet (22) is provided between the upper portion of the vat (4) and the condenser device (13) and includes an upstream section (24) integral with the lid (8) and having one end (25) in communication with the upper portion of the vat (4), and a downstream section (27) connecting the other end (26) of the upstream section with the condenser device (13). This system is suitable for household deep fryers.

Abstract: Purified polypeptides containing characteristic sequences common to the pyrrolidone carboxylyl peptidases (PYRases) of bacteria, for example of Streptococcus pyogenes, or containing fragments of these sequences; antibodies recognizing these polypeptides; polynucleotides coding for such polypeptides or fragments.Application, in particular, to the overproduction of PYRases by inserting a polynucleotide coding for a PYRase into a vector, and then culturing a host cell transformed using such a vector, or to the production of nucleic acid probes specific for a bacterium having a PYRase gene, expressed or otherwise. These nucleic acid probes may be used as capture or detection probes according to conventional hybridization techniques.

Abstract: A method of producing a fibre-reinforced metallic circular part having a tral hollow, wherein the reinforcing fibres are disposed in the part in the vicinity of the hollow, comprises providing an annular metallic blank with a channel-sectioned groove opening towards the axis of the blank, placing uncompressed concentric layers of the reinforcing fibres and additional metal alternately in the groove followed by a more rigid expansion ring, evacuating the groove and sealing it by a deformable closure member which covers the groove, placing this assembly in an autoclave and subjecting it to a temperature and pressure sufficient to effect superplastic forging of the layers of additional metal whereby the fibre layers and the additional metal layers are compressed and welded to the blank in a single operation, and machining the resulting assembly to obtain the required shaped part.

Abstract: Compounds of the formula ##STR1## or a pharmaceutically acceptable salt or ester thereof, wherein R.sup.1 is selected from the group consisting of hydrogen and C.sub.1-10 alkyl;R.sup.2 is selected from the group consisting of hydrogen and C.sub.1-10 alkyl;R.sup.3 is selected from the group consisting of C.sub.1-10 alkoxyl, C.sub.1-10 alkyl and cyano;R.sup.4 is selected from the group consisting of C.sub.1-10 alkenyloxyl, C.sub.1-10 alkoxyl, C.sub.1-10 alkyl, C.sub.1-10 alkylcarbamic, C.sub.1-10 alkylcarbonyloxyl, carbonyl, hydroxyl, and --NHR.sup.5, andR.sup.5 is selected from the group consisting of hydrogen and C.sub.1-10 alkylcarbonyl. Such compounds are useful as selective antagonists of testosterone 5.alpha.-reductase 1.

Abstract: This invention relates to interleukin inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.

Abstract: The apparatus is adapted to be held in one hand of an operator from mixing components of a composition packaged as two or more individually stable components of substantially equal volume and viscosity each in a receptacle having a closure made of a material which can be ruptured, and to dispense the mixed composition by a manual operation. The device comprises a mixing housing, separate chambers for the receptacles, piercing means for piercing the receptacles, plunger means for expelling a component from the chamber into the mixing region, a mixing element in the mixing region, and a passageway which contains means for actuating the mixing element and through which the mixed composition may be expelled from the mixing region.

Abstract: Cyclosporin analogs containing a MeAla or MeAbu residue at the 6-position of the cyclic undecapeptide have been discovered to sensitize multidrug resistant cells to certain chemotherapeutic agents. These cyclosporin analogs have also been shown to increase the sensitivity of cells already susceptible to the chemotherapeutic agents. In addition, these cyclosporin A analogs lack the nephrotoxic and immunosuppressive activity of cyclosporin A.

Abstract: New immunosuppressive cyclosporin analogs are disclosed having one or more fluorinated amino acids. These analogs may also have a "C-9 amino acid" wherein the double bond is replaced by a heteroatom such as sulfur or oxygen.

Abstract: A multi-component foamable silicone composition is described and claimed which is capable of curing quickly at 20.degree. C. to provide a low density foamed mass. The composition comprises (A) one or more polydiorganosiloxanes having not less than three alkyl-hydrogensiloxane units per molecule, (B) one or more polydiorganosiloxanes having not less than two alkenyl-siloxane units (C) a liquid alcohol, (D) a fluorinated silicone foam stabilizing material and (E) a platinum catalyst for promoting reaction between the components. The composition may be packaged as two or more individually stable parts of substantially equal volume and viscosity each in a receptacle of material which is adapted to be opened by rupture so as to release the components for admixture. The composition is intended for use in forming a foam medical dressing by dispensing onto a surface e.g. an open wound and allowing the composition to cure at room temperature.

Abstract: New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described.

Abstract: New substituted azetidinones of the general formula (A), which have been found to be potent elastase inhibitors and thereby useful as anti-inflammatory and antidegenerative agents, are described.

Abstract: Method for increasing resistance to gastro-intestinal irritation, and for the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandin and/or leukotriene mediated diseases comprising the administration to a subject in need of such treatment, a non-toxic therapeutically effective amount of compound of formula I: ##STR1##

Abstract: The pincers comprise a gripping head (1) and a control device (2). The control device (2) contains a direct-current electric motor (12-13) which is supplied, through a control circuit (38), from a current-feed source (39). In addition, it comprises a commutable system of permanent magnets. The rotor (12) of the motor is integrally locked to an axle (11) which is capable of actuating the gripping head (1), which is installed in the body of the control device (2), and which is displaceable axially between two positions. The stator (13) is installed in such a way as to be free to revolve between two limiting angular positions and is integrally locked to a first part (27-28) of the commutable system of permanent magnets, which is integrally locked to a support (15) of the axle (11). The second part (29-30) is integrally locked to the body of the control device (2). These two parts are attracted to each other when the stator (13) is occupying its first angular position.

Abstract: Disclosed are pharmaceutical compositions for enhancing human host resistance against opportunistic infection in an individual immunocompromised by an AIDS-related virus, consisting essentially of an anti-viral, anti-AIDS drug selected from the group consisting of ansamycin, ribavirin, dideoxycitidine, HPA-23, AL-721, foscarnet, and azidothymidine and a glycolipid compound consisting essentially of the formula: ##STR1## where: R.sup.1 is .alpha. or .beta.-D-1-thiomannopyranoside, .alpha. or .beta.-L-1-thiofucopyranoside.